key: cord-0927868-x18xttd5
authors: Mazzitelli, Ignacio; Bleichmar, Lucia; Ludueña, María Guillermina; Pisarevsky, Andrea; Labato, Mariana; Chiaradia, Verónica; Finocchieto, Paola; Paulin, Francisco; Hormanstorfer, Macarena; Baretto, María Constanza; Adanza, Santiago Piombi; Parodi, María Noel; Ragusa, Martín; Melucci, Claudia; Díaz, Fernando Erra; Paletta, Ana; Di Diego, Facundo; Ceballos, Ana; Geffner, Jorge
title: IgG immune complexes may contribute to neutrophil activation in the course of severe COVID-19
date: 2021-04-02
journal: J Infect Dis
DOI: 10.1093/infdis/jiab174
sha: 0a2185444496e6f15c2626d6e85e87939047d681
doc_id: 927868
cord_uid: x18xttd5

Severe COVID-19 is associated with an overactive inflammatory response mediated by macrophages. Here, we analyzed the phenotype and function of neutrophils in COVID-19 patients. We found that neutrophils from severe COVID-19 patients express high levels of CD11b and CD66b, spontaneously produce CXCL8 and CCL2 and show a strong association with platelets. Production of CXCL8 correlated with plasmatic concentrations of LDH and D-dimer. Whole blood assays revealed that neutrophils from severe COVID-19 patients show a clear association with IgG immune complexes. Moreover, we found that sera from severe patients contain high levels of immune complexes and activate neutrophils through a mechanism partially dependent on FcγRII (CD32). Interestingly, when integrated in immune complexes, anti-SARS-CoV-2 IgG antibodies from severe patients displayed a higher pro-inflammatory profile compared with antibodies from mild patients. Our study suggests that IgG immune complexes might promote the acquisition of an inflammatory signature by neutrophils worsening the course of COVID-19.

A c c e p t e d M a n u s c r i p t 3 BACKGROUND SARS-CoV-2 infection induces a wide spectrum of clinical manifestations ranging from asymptomatic to severe disease and death [1] . Disease severity is associated to the induction of a systemic inflammatory response revealed by the high levels of inflammatory cytokines, chemokines and inflammatory markers such as C-reactive protein (CRP), ferritin, D-dimer, and LDH found in patients with severe COVID-19 [2] . Aberrant immune response in the lung is associated not only with severe COVID-19 but also with a variety of respiratory viral infections including those mediated by respiratory syncytial virus (RSV) and influenza A virus (IAV) [3, 4] . Neutrophils are the predominant cell type infiltrating the lung during severe RSV infection, and it has been demonstrated that they do not only promote epithelial cell damage and mucus overproduction but also enhance susceptibility to RSV infection [4, 5] . Regarding IAV infection, it has been shown that patients with severe disease show a massive infiltration of the airway by neutrophils and an excessive production of neutrophil extracellular traps (NETs) being both responses associated with fatal outcome in experimental models and humans [6] .

Macrophages are the major source of inflammatory cytokines in the course of severe COVID-19 [7] . By contrast, the contribution of neutrophils is not well defined. While contradictory reports have been published regarding the degree of airway infiltration by neutrophils in severe COVID-19 [8, 9] , a large body of evidence suggest that neutrophils actually play a major role in the pathogenesis of severe COVID-19 [10, 11] . Here, we show that neutrophils from severe COVID-19 patients display an activated phenotype, spontaneously produce CXCL8, and show a strong association with platelets. Moreover, our results suggest that IgG immune complexes (ICs) might contribute to the acquisition of an inflammatory phenotype by neutrophils in the course of severe COVID-19. 

Our study was approved by the Ethics Committees of the "Hospital de Clínicas José San Martín" and "Hospital Fernández" (Argentina), in accordance with the Declaration of Helsinki (Fortaleza 2013). Written informed consent was obtained from all donors or legal guardians.

Healthy individuals (n=42) were recruited from the blood bank of the "Hospital de Clínicas José San Martín": age range 23-65 years, male 62%. COVID-19 patients (n=67) were recruited from the "Hospital de Clínicas José San Martín" and the "Hospital Fernández". All COVID-19 patients were diagnosed by PCR amplification of SARS-CoV-2 viral RNA obtained from nasopharyngeal or oropharyngeal swabs. Taking into account the World Health Organization´s (WHO) eight-point scale for COVID-19 trial endpoints, patients were classified into three stages, i.e., mild, moderate, and severe [12] . Mild COVID-19 patients (WHO scores 1-2) were ambulatory patients or patients hospitalized with the aim of keeping them isolated; moderate patients (scores 3-4) included those with little or no requirement for supplemental oxygen; and severe patients included those with high-flow oxygen requirement (score 5), intubation and mechanical ventilation (score 6), and multi-organ support (score 7).

Disease severity was recorded at the time of sampling. Patient characteristics are shown in Table 1. A c c e p t e d M a n u s c r i p t 5

Neutrophils were isolated from heparinized blood samples by centrifugation on Ficoll-Paque (GE Healthcare, Argentine) and dextran (Sigma-Aldrich) sedimentation. Contaminating erythrocytes were removed by hypotonic lysis. After washing, the cell pellets (>98% of neutrophils on May-Grunwald-Giemsa-stained cytopreparations) were suspended in RPMI-1640 medium (Gibco Invitrogen, CA, USA). Neutrophils purity was confirmed by flow cytometry considering the forward (FSC) and side scatter (SSC) neutrophil properties, the high expression of CD66b, and the very low expression of CD14 that allows to distinguish neutrophils from monocytes. Peripheral blood mononuclear cells were isolated from the Ficoll-Paque gradient and monocytes were purified by positive selection using anti-CD14coated magnetic beads (Miltenyi Biotec, CA, USA) (% purity 89-97%).

Labeled monoclonal antibodies (mAbs) directed to CD11b, CD14, CD41, CD66b, CD62L (L-selectin), CXCR1, CD62P (P-selectin), IgG, and isotype controls were from BD Biosciences (CA, USA). Data were acquired using a BD FACSCanto cytometer and BD FACSDiva software (BD Biosciences). Statistical analyses were based on at least 20000 events gated in the neutrophil gate, defined as described above.

It was studied by flow cytometry in whole blood samples by analyzing the platelet markers Pselectin (CD62P) or CD41 in the neutrophil gate. Briefly, whole blood samples were 

It was carried out using a Corning HTS Transwell 96 permeable supports (5 M pore size) (Corning, NY, USA). Unstimulated neutrophils (10 × 10 6 /ml) from healthy donors (HD) or severe COVID-19 patients were cultured at 37°C for 18 h, and supernatants were collected.

Healthy neutrophils (1.5x10 5 /100 l) were added to the upper reservoir and neutrophil supernatants (100 l), IL-8 (10 ng/ml) or culture medium (control) were added to the lower reservoir. After 1 h at 37°C, neutrophils in the upper and lower chamber were quantified by flow cytometry, and the percentage of neutrophils that have migrated was determined.

It was analyzed by flow cytometry in whole blood samples or isolated neutrophils. Whole blood assays were performed by analyzing the presence of IgG antibodies associated to the neutrophil surface in freshly heparinized blood samples previously washed five times with culture medium. Cells were stained with a FITC-labeled mAb directed to IgG, and samples were treated with BD FACS™ lysing solution prior to acquisition. Assays with isolated healthy neutrophils were performed by incubating neutrophils with serum (10%) from HD or COVID-19 patients for 1 h at 4°C. Experiments were performed at 4°C to avoid the internalization of IgG antibodies attached to the neutrophils surface. Then, cells were washed and IgG binding was revealed by staining with a labeled mAb directed to IgG.

It was performed by polyethyleneglycol (PEG) precipitation [13] . Briefly, 0. 

Neutrophils (2x10 6 /ml) were cultured for 10 h at 37°C in RPMI medium supplemented with 10% FCS, and annexin-V binding to apoptotic neutrophils was carried out using an apoptosis detection kit (BD Biosciences).

It was evaluated by using the indicator dye dihydrorhodamine-123 (Molecular Probes, CA, USA) by flow cytometry. Neutrophils (2×10 6 /ml) were labeled with dihydrorhodamine-123 and cultured for 30 min at 37°C without stimuli or in the presence of serum (10%) from HD or COVID-19 patients. In some experiments, neutrophils were pre-treated with a blocking antibody directed to FcγRII (clone IV.3, STEMCELL, FL, USA).

The presence of CXCL8, CCL2, TNF-α and IL6 in cell supernatants was analyzed by ELISA (Biolegend, CA, USA).

It was performed by ELISA using the "COVIDAR IgG" kit (Laboratorio Lemos SRL, Buenos Aires, Argentina) that detects IgG antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein [14] .

A c c e p t e d M a n u s c r i p t 8

We screen a large number of sera from COVID-19 patients by ELISA (COVIDAR IgG) and selected a panel of sera with high-titers (1:3200) of anti-SARS-CoV-2 IgG antibodies from severe or mild patients, that were used to prepare ICs and stimulate healthy neutrophils and monocytes. The titers of all sera were normalized to 1:3200. Then, sera from severe and mild patients were incubated for 1 h at room temperature in the plate of COVIDAR IgG kit, that contains two immobilized antigens of SARS-CoV-2, the trimeric spike protein and the RBD domain, prepared as described [14] . Plates were washed five times, and 1.5x10 5 neutrophils or 1x10 5 monocytes suspended in 100 l of culture medium supplemented with 10% FCS were added. Release of hydrogen peroxide, expression of CD11b and production of cytokines were analyzed.

When two groups were present, normally-distributed data were analyzed by two-sided t test 

All patients were diagnosed with COVID-19 by PCR amplification of SARS-CoV-2 viral RNA obtained from nasopharyngeal or oropharyngeal swabs. Patients were classified as mild, moderate or severe as described in Methods. Neutrophil activation is associated with phenotype changes such as the up-regulation of CD11b and CD66b, and L-selectin loss. We found that neutrophils isolated from severe COVID-19 patients, but not from patients with mild or moderate disease, showed a higher expression of CD11b and CD66b compared with HD ( Figure 1A) . A lower expression of L-selectin was also observed in severe patients, although it did not reach statistical significance when compared with HD ( Figure 1B) .

Considering previous studies showing that the interaction with platelets promotes neutrophils activation [15, 16] , we analyzed whether neutrophils from COVID-19 patients showed a greater tendency to interact with platelets. It was analyzed by flow cytometry in whole blood samples by studying the presence of the platelet markers P-selectin (CD62P) or CD41 in the neutrophil gate. Neutrophils from severe COVID-19 patients showed a higher association with platelets compared with healthy donors (Figure 1C) . Moreover, a positive correlation was found between the degree of neutrophil-platelet association and the days of hospitalization ( Figure 1C , right panel). No differences in the rate of apoptosis was observed for neutrophils isolated from patients or HD (Figure 1D ).

High serum IL6, CXCL8 and TNF-α levels at the time of hospitalization are predictors of COVID-19 patient survival [17] . We evaluated the spontaneous production of IL6, TNF-α and CXCL8 by neutrophils isolated from COVID-19 patients. No production of IL6 and TNF-α was observed (not shown). By contrast, neutrophils from severe COVID-19 patients spontaneously produced CXCL8 (Figure 2A, left) . This production correlated with two recognized markers of disease severity, the plasmatic concentrations of LDH and D-dimer (Figures 2A) [2, 18] . Consistent with the ability of CXCL8 to induce the internalization of the CXCL8 receptor CXCR1 [19] , neutrophils from severe COVID-19 patients showed a lower expression of CXCR1 compared with HD ( Figure 2B) . A higher spontaneous production of the chemokine CCL2 by isolated neutrophils from severe COVID-19 patients was also observed although it did not reach statistical significance when compared with HD ( Figure 2C) . Moreover, we found that neutrophil supernatants from severe COVID-19 patients induced a strong chemotactic response on healthy neutrophils (Figure 2D) .

Considering that severe disease is associated not only with the production of high levels of anti-SARS CoV-2 IgG antibodies but also with the production of IgG autoantibodies [20] [21] [22] , we analyzed the role of IgG antibodies and immune complexes (ICs) in neutrophil activation.

Interestingly, flow cytometer analysis performed in whole blood samples revealed high levels of neutrophil-associated IgG antibodies in severe COVID-19 patients (Figure 3A) . Pretreatment of whole blood samples with a FcR blocking reagent (Miltenyi Biotec) almost completely displaced IgG antibodies from the neutrophil surface, suggesting that neutrophils bind IgG in a FcγR-dependent mode and not through the recognition of neutrophil surface antigens by the Fab portion of IgG antibodies. Consistent with these observations, we found that serum concentrations of ICs were significantly higher in severe COVID-19 patients compared with healthy donors (Figure 3A, right panel) . We then analyzed whether sera from COVID-19 patients might be able to induce the activation of healthy neutrophils in a FcγR-dependent mode. Incubation of neutrophil isolated from healthy donors with sera from severe COVID-19 patients resulted not only in the binding of IgG ICs (Figure 3B ), but also in the activation of the neutrophil respiratory burst (Figure 3C) , being this response significantly prevented by a blocking antibody directed to FcγRII (Figure 3D) .

A c c e p t e d M a n u s c r i p t 11 To gain insight into the mechanisms underlying the activation of healthy neutrophils by sera from COVID 19 patients, we analyzed the impact of two variables: disease severity and titers of anti-SARS-CoV-2 IgG antibodies. Sera from severe and mild COVID-19 patients were titrated by an ELISA to detect anti-SARS-CoV-2 IgG antibodies (see Methods). In agreement with previous reports [23, 24] , we observed that sera from severe patients showed higher antibody titers compared with mild patients (not shown). By screening a large number of sera, we could select a panel of sera with high (1:3200) and low-titers (<1:100) of IgG anti-SARS-CoV-2-antibodies from either severe or mild patients, and analyzed their ability to activate the respiratory burst of healthy neutrophils. High titers of specific IgG antibodies were shown to be associated with a high ability to trigger the respiratory burst of neutrophils isolated from healthy donors. Interestingly, sera from severe patients show a higher ability to induce the activation of the neutrophil respiratory burst when compared with sera from mild patients with similar titers of anti-SARS-CoV-2 IgG antibodies ( Figure 4A) .

its affinity for FcγRIII [25] . Recent reports indicated that anti-SARS-CoV-2 IgG antibodies in severely ill COVID-19 patients show a unique ability to trigger FcγRIIIa-dependent inflammatory responses by macrophages due to a reduced fucosylation at the Fc portion of IgG [26] . We analyzed whether IgG antibodies directed to the SARS-CoV-2 spike protein from severe and mild COVID-19 patients differed in their ability to induce neutrophil activation. To this aim, all sera were adjusted to a final titer of 1:3200, and different sera dilutions were incubated with immobilized S protein for 1 h in 96 well plate flat bottom.

Then, wells were washed and neutrophils isolated from healthy donors suspended in RPMI medium supplemented with 10% FCS were added, and plates were incubated for 30 min at 37°C. As shown in Figure 4B , ICs effectively induced the activation of the neutrophil A c c e p t e d M a n u s c r i p t 12 respiratory burst when serum dilutions of 1:10 and 1: 20 were used. Using sera at a final dilution of 1:20, neutrophil activation was analyzed by measuring respiratory burst activation, up-regulation of CD11b expression and CXCL8 production. No differences were observed between the responses induced by IgG antibodies from severe and mild COVID-19 patients regarding neutrophil respiratory burst activation, by contrast a higher CD11b expression and an increased stimulation of CXCL8 production was observed for neutrophils activated by IgG antibodies from severe patients (Figure 4 C and D left panel) . We then performed a similar analysis using isolated monocytes. ICs failed to induce the production of TNF-α and IL6 (not shown), but efficiently induced the production of CXCL8, being this response significantly higher for ICs prepared with IgG antibodies from severe patients (Figure 4D right panel) .

We conclude that ICs prepared with anti-SARS-CoV2 IgG antibodies from severe COVID-19 patients show a higher inflammatory profile compared with IgG antibodies from mild patients.

Inflammation is a hallmark of severe COVID-19 but the players and the mechanisms involved in the onset and exacerbation of the inflammatory response remain poorly defined.

It was assumed that SARS-CoV-2-induced lung dysfunction is associated with a strong storm of inflammatory cytokines but a rigorous comparison with other inflammatory syndromes such as sepsis, cytokine release syndrome, and acute respiratory distress revealed serum IL6 concentrations among 10 to 100 fold lower in severe COVID-19 [27] . In contrast, various non-cytokine markers of inflammation and tissue injury such as D-dimer, C-reactive protein, ferritin, and lactate dehydrogenase (LDH) are increased in a similar fashion in severe-COVID-19 and other critical inflammatory diseases [27] , suggesting that systemic High numbers of neutrophils have been found in the bronchoalveolar lavage fluid of patients with severe COVID-19 [8, 9, 28] . Elevated blood neutrophil counts have shown to predict worse outcomes in COVID-19 [29] , while increased concentrations of neutrophils products such as neutrophil extracellular traps (NETs) [30] , myeloperoxidase (MPO) , and calprotectin [31] have been described in patients with severe-COVID-19. A large body of evidence suggests that NETs play a major role in the pathogenesis of severe COVID-19. NETs components have been detected in the plasma of patients with severe COVID-19 and correlated with disease severity [11, 32, 33] . Moreover, NET-containing microthrombi with neutrophil-platelet infiltration has been described in pulmonary autopsies from patients died from COVID-19 [32] , suggesting that NETs triggering immunothrombosis is involved in the pathogenesis of severe COVID-19. Neutrophils could also contribute to thrombotic events in the course of COVID-19 by releasing neutrophil-derived microparticles [33] . They have been associated to thrombosis in different diseases [34, 35] and have been found at high concentrations in the plasma of COVID-19 patients [33] . Interestingly, the activation of neutrophils and platelets in the course of COVID-19 could be induced not only by inflammatory mediators, but also directly by interacting with SARS-CoV-2 [30, 36, 37] .

We here show that neutrophils from severe COVID-19 patients, but not from patients with mild or moderate disease, display an activated phenotype and spontaneously produce CXCL8 and CCL2. Production of CXCL8 correlated with the plasmatic concentrations of LDH and D-dimer, two recognized markers of disease severity [2, 18] . Consistent with previous reports [32, 38] , we found that neutrophil from severe COVID-19 patients interact with platelets, and A c c e p t e d M a n u s c r i p t 14 a correlation between the degree of neutrophil-platelet interaction and the days of hospitalization was found.

Neutralizing IgG antibody titers have shown to be higher in severe COVID-19 compared with mild or moderate disease [23, 24] , calling into question whether IgG antibodies might also be involved in the pathogenesis of COVID-19. No evidence has been published supporting a role for antibody-dependent enhancement of infection in COVID-19. However, IgG antibodies might contribute to disease severity not only by promoting viral infection, but also by inducing inflammatory responses. In fact, studies performed in SARS-CoV/macaque models showed that IgG antibodies against the SARS-CoV-2 spike protein increases the severity of lung injury by promoting an inflammatory response mediated by macrophages [39] .

The drivers of inflammation in COVID-19 remain to be clarified. Little attention has been paid to the possible role of IgG ICs. However, different observations suggest that IgG ICs might in fact be involved in the pathogenesis of severe COVID-19: a) severe disease is associated with high levels of circulating anti-SARS-Cov-2 IgG antibodies [23, 24] , b) viral antigens have been found in the blood of patients [40, 41] , c) systemic complement activation occurs in the course of severe COVID-19 [42] ; d) severe infection is associated to an exaggerated extrafollicular B cell response [43] , and the production of a variety of autoantibodies directed to red blood cells [22] , platelets [21] , type-I interferons [20] , selfcarbohydrates [44] , self-phospholipids [45] , antinuclear antibodies (ANAs), and anticytoplasmic neutrophil antibodies (ANCAs) [46] . Our present results suggest not only that IgG ICs promote neutrophil activation in the course of severe COVID-19 but also that ICs might play a role in the induction of the systemic inflammatory and thrombotic responses A c c e p t e d M a n u s c r i p t 15 associated with severe COVID-19. Interestingly, it has been recently reported that sera from severe COVID-19 patients contain ICs that activate platelets through FcγRIIA [47] . Our results also suggest that anti-SARS-IgG antibodies from severe patients express a unique proinflammatory profile when incorporated into ICs. This observation is consistent with previous studies showing that ICs containing anti-spike IgG antibodies from severely ill COVID-19 patients induce a hyper-inflammatory response mediated by monocytes, macrophages and NK cells, due to a reduced fucosylation of the Fc fragment of IgG antibodies directed to SARS-CoV-2, resulting in an enhanced affinity to FcγRIII [26, 48] . (A) IgG binding to neutrophils was evaluated in freshly whole blood samples from HD or severe COVID-19 patients, by staining with a FITC-labeled antibody directed to human IgG.

In some experiments, whole blood samples were treated with a FcR blocking reagent before staining. Bars represent the MFI mean ± S.E. (n=4-12) after subtraction of the mean value of the isotype. Right panel shows the concentration of serum ICs from healthy donors (n = 30) and severe COVID-19 patients (n = 37), indicated as PEG index. (B) Isolated neutrophils (2x10 6 /ml) were incubated in culture medium supplemented with 10% serum from HD or severe COVID-19 patients for 1 h at 4°C. Then, cells were stained with a PE-labeled antibody directed to human IgG and analyzed by flow cytometry. A representative experiment (n=3) performed with sera from HD (n=5) or sera from severe COVID patients (n=8) is shown.

(C) Purified healthy neutrophils (2x10 6 /ml) were labelled with

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice

Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection

Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis

High Level of Neutrophil Extracellular Traps Correlates With Poor Prognosis of Severe Influenza A Infection

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Targeting potential drivers of COVID-19: Neutrophil extracellular traps

Immune dysfunction following COVID-19, especially in severe patients

Neutrophil extracellular traps in COVID-19

A minimal common outcome measure set for COVID-19 clinical research

The use of polyethyleneglycol for immune complex detection in human sera

Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina

Neutrophils scan for activated platelets to initiate inflammation

P-selectin promotes neutrophil extracellular trap formation in mice

An inflammatory cytokine signature predicts COVID-19 severity and survival

An interpretable mortality prediction model for COVID-19 patients

beta-arrestins regulate interleukin-8-induced CXCR1 internalization

Autoantibodies against type I IFNs in patients with lifethreatening COVID-19

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Positive direct antiglobulin tests in patients with COVID-19

Kinetics of viral load and antibody response in relation to COVID-19 severity

Antibody responses to SARS-CoV-2 in patients with COVID-19

Functional diversification of IgGs through Fc glycosylation

Proinflammatory IgG Fc structures in patients with severe COVID-19

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology

Associations of procalcitonin, C-reaction protein and neutrophil-tolymphocyte ratio with mortality in hospitalized COVID-19 patients in China

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease

Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease

Phosphotidylserine exposure and neutrophil extracellular traps enhance procoagulant activity in patients with inflammatory bowel disease

SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19

Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19

Neutrophil-Platelet and Monocyte-Platelet Aggregates in COVID-19 Patients

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Serial Profiling of SARS-CoV-2 Antigens and Antibodies in COVID-19 Patient Plasma

Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Abnormal antibodies to self-carbohydrates in SARS-CoV-2 infected patients

Presence of antiphospholipid antibodies in COVID-19: case series study

COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful?

Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

2020representative experiment (n=3) performed with sera from HD (n=29) or sera from mild (n=8) or severe COVID patients (n=26) is shown. (D) Neutrophils were pretreated, or not, with a blocking mAb directed to FcγRII (clone IV.3), and production of hydrogen peroxide induced by serum (10%) from severe COVID-19 patients (n=15) was analyzed as described in (C). A representative experiment (n=3) is shown. Kruskal-wallis test was used for comparisons in A center

test was used in A center left panel and right panel; and paired t test was used in D. Histograms and dot-plots show representative experiments

Inflammatory IgG antibodies anti-SARS-CoV-2 in severe COVID-19 patients

A panel of sera with high (1:3200) and low-titers (<1:100) of IgG anti-SARS-CoV-2

HD (n=24), or mild patients/low titers (n=23), mild patients/high titers (n=23), severe patients/low titers (n=24) and severe patients/high titers (n=24) is shown. (B-D) Sera from severe and mild COVID-19 patients containing high levels of IgG antibodies anti-SARS

Sera from HDs were used as controls. Different sera dilutions (B) or 5% of normalized sera (C-D) were incubated with immobilized SARS-CoV-2 antigens (trimer spike protein and RBD domain of spike protein)

We thank all the team members of the "Departamento de Medicina Interna, "Hospital de Clínicas José San Martín" and the "Servicio de Clínica Médica, Hospital Fernández", Argentina. Most of all, we are indebted to all the participating in our study and their families.

This work was supported by grants from the "Fondo Nacional para la Investigación Científica 

All authors report no potential conflicts. 

A c c e p t e d M a n u s c r i p t 17 A c c e p t e d M a n u s c r i p t 18 A c c e p t e d M a n u s c r i p t 19 A c c e p t e d M a n u s c r i p t 23 1.5x10 5